Dergiler / Anadolu Kardiyoloji Dergisi / 2014 / Cilt: 14 - Sayı: 2

Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome

Sayfa
134–139
Yayın Tarihi
2022-10-10
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Mean MPV was found to be significantly higher in nonresponders compared to responders (8.7±0.82 fL vs. 8.1±0.83 fL, p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Clopidogrel therapy is the standard of care in patients with acute coronary syndrome (ACS) and stent implantation.
📊
Temel Bulgular & Veri:However, con- cern arises because 25% of subjects are nonresponders to clopidogrel.
💡
Sonuç & Katkı:Mean MPV was found to be significantly higher in nonresponders compared to responders (8.7±0.82 fL vs. 8.1±0.83 fL, p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Clopidogrel therapy is the standard of care in patients with acute coronary syndrome (ACS) and stent implantation. However, con- cern arises because 25% of subjects are nonresponders to clopidogrel. As this nonresponsiveness is associated with increased adverse out- come, detection of these subjects in daily practice is important in order to withhold a more aggressive therapy and closer follow up. In this study we aimed to evaluate the relation between mean platelet volume (MPV) which is an indicator of platelet activation and clopidogrel nonrespon- siveness. Methods: The study was planned as a prospective cohort study. A total of 185 patients who had been on clopidogrel therapy for any acute coronary syndrome were enrolled in this study. Clopidogrel responsiveness was analyzed by Multiplate MP-0120 device by using the method of whole blood aggregometry. Blood samples were drawn 3.5 days after clopidogrel loading dose. The amount of ADP induced platelet aggrega- tion was assessed as area under curve (AUC), and a cut-off value of 500, above which the patient is considered as clopidogrel nonresponder, was used. MPV was analyzed from the blood which were sampled at the admission of the patient by using automatic hemocounter. Independent sample t-test, ROC analyses and logistic regression analsis were used in statistical analysis. Results: Among the 185 patients analyzed 41 were found to be clopidogrel nonresponder (22.1%). Mean MPV was found to be significantly higher in nonresponders compared to responders (8.7±0.82 fL vs. 8.1±0.83 fL, p

🔖

Bu Makaleye Atıf Yap

UZEL, H., ÖZPELİT, E., BADAK, Ö., AKDENİZ, B., BARIŞ, N., AYTEMİZ, F., GÖLDELİ, Ö. (2022). Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome. Anadolu Kardiyoloji Dergisi, Cilt: 14 - Sayı: 2, 134–139. https://ajindex.com/articles/436084

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001
  2. [CrossRef] 2. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001
  3. [CrossRef] 3. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO). JAMA 2002
  4. [CrossRef] 4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001
  5. [CrossRef] 5. Sabatine MS, Cannon CP Gibson CM, López-Sendón JL,, Montalescot G, Theroux P et al. CLARITY-TIMI 28 Investigators., Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005
  6. [CrossRef] 6. Chen ZM, Jiang LX, Chen YP Peto R, Collins R, Jiang LX, et al., COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005
  7. [CrossRef] 7. Güray Y, Güray Ü, Korkmaz Ş. Clopidogrel resistance. Anadolu Kardiyol Derg 2009
  8. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004
  9. [CrossRef] 9. Park Y, Schone N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002
  10. [CrossRef] 10. Martin JF, Bath PM, Burr M. Influence of platelet size on outcome after myocardial infarction. Lancet 1991
  11. [CrossRef] 11. Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, et al. Mean platelet volume is an independent risk factor for my